Invariant natural killer T cells reconstitution and the control of leukemia relapse in pediatric haploidentical hematopoietic stem cell transplantation by Casorati, Giulia et al.
www.landesbioscience.com  OncoImmunology  355
OncoImmunology 1:3, 355-337; May/June 2012; © 2012 Landes Bioscience
 EDITOR’S CAORNER AUTHOR’S VIEW
Invariant natural killer T cells reconstitution 
and the control of leukemia relapse in pediatric 
haploidentical hematopoietic stem cell 
transplantation
Giulia Casorati,* Claudia de Lalla and Paolo Dellabona
Experimental immunology Unit; Division of Immunology; Transplantation and Infectious Diseases; San Ra aele Scienti c Institute; Milano, Italy
Keywords: NKT cells, CD1d, immunesurveillance, leukemia, immunotherapy
*Correspondence to: Giulia Casorati; Email: casorati.giulia@hsr.it
Submitted: 10/07/11; Revised: 10/11/11; Accepted: 10/13/11
http://dx.doi.org/10.4161/onci.18399
CD1d-restricted invariant (i)NKT cells are innate-like, lipid-reactive T lymphocytes implicated in the control of infections, 
cancer and autoimmunity. Our study suggests that the reconstitution of the peripheral iNKT cell compartment, following 
HLA-haploidentical hematopoietic stem cell transplantation, associates with leukemia control in children a ected by 
di erent hematological malignancies.
Invariant natural killer T (iNKT) cells are 
innate-like  T  lymphocytes  bearing  con-
served  invariant  V_14-J_18  V_24-J_18 
TCR chains in mice and humans, respec-
tively, paired with V`8, V`7 and V`2 in 
mice  and  V`11  in  humans.1  iNKT  cells 
recognize  microbial  and  cell-endogenous 
lipids  presented  by  the  MHC  class  I-like 
molecule CD1d.1 iNKT cells acquire con-
stitutive  effector  functions  following  lin-
eage-dependent developmental cues, which 
enables them to rapidly respond to a variety 
of  stimuli  without  prior  Agsensitization. 
Upon activation, iNKT cells produce copi-
ous amounts of different cytokines and they 
have been implicated in the early control of 
cell stress and tissue damage related to infec-
tions, cancer and autoimmunity.1
The  HLA-haploidentical  hematopoietic 
stem cell transplantation (hHSCT) is a criti-
cal therapy for the great majority (75%) of 
leukemia patients lacking an HLA-identical 
sibling.2 T h e  t r a n s f e r  o f  H S C  f r o m  r e l a -
tives that only share half HLA locus with 
the  recipients  permits  to  ﬁnd  an  immedi-
ate donor for any patient.2 Puriﬁed do n o r -
derived HSC are depleted of mature T cells 
to reduce the risk of GVHD, triggered by the 
donor/recipient  histocompatibility  barrier, 
and infused into patients who are profoundly 
myeloablated to eliminate both endogenous 
hemopoiesis and malignant cells.2 As a result, 
the  immune  system  that  reconstitutes  in 
the recipients derives from the donor HSCs, 
which  generate  lymphoid  precursors  that 
seed in the thymus and give raise to the T 
and  iNKT  lymphocytes  that  are  exported 
in the periphery.3 This process is particularly 
efﬁcient in pediatric patients who maintain a 
functional thymus.3 A rapid immunorecon-
stitution is critical to control the major life 
threatening events that may occur following 
hHSCT, such as opportunistic infections and 
the leukemia recurrences.3 In light of these 
characteristics, we thought that hHSCT in 
pediatric patients with leukemia was a suit-
able model to investigate human iNKT cell 
reconstitution, to address the unsolved issues 
of their maturation dynamics and their role 
in leukemia relapse control. Due to the dif-
ﬁculty to follow longitudinally the iNKT cell 
development in healthy donors, only snap-
shots on the human iNKT cell development 
at initial (thymus and umbilical cord blood) 
or  late  (adult  blood)  stages  were  available 
from cross-sectional studies, showing that: (1) 
Thymic and neonatal iNKT cells display an 
immature CD4+ phenotype lacking CD161, 
the NK terminal differentiation marker, and 
poor effector cytokine production;4 (2) adult 
mature circulating iNKT cells are divided into 
two main CD4+CD161+ TH0 helper/regula-
tory and CD4- CD161+ (mainly CD4-CD8-) 
TH1  effector/inﬂammatory  subsets  with  a 
CD4- A CD4+ ratio.5,6 However, the dynam-
ics  by  which  an  immature  fetal  CD4+161- 
precursor  generates  the  two  adult  mature 
CD4+CD161+ a n d  C D 4 -CD161+  iNKT 
cell  subsets  was  unknown.  On  the  other 
hand, evidence in mouse models and cancer 
patients suggested that iNKT cells participate 
in the immune surveillance of different solid 
tumors, lymphoma and multiple myeloma.7 
Pre-clinical studies also elucidated the iNKT 
cell role in determining the positive balance 
between GVL and GVHD in mouse models 
of HSCT for leukemia.8 Hence, the potential 
control of leukemia relapses by human iNKT 
in the clinically relevant context of hHSCT 
was an important question. 
In  our  study,9  we  undertook  a  thor-
ough  longitudinal  analysis  of  iNKT  cell 
reconstitution  in  22  consecutive  pediat-
ric  patients  undergoing  hHSCT  after  a 
myeloablative regimen for the treatment of 
acute  leukemia  and  myelodysplastic  syn-
dromes (Fig. 1A). CD4+ and CD4- iNKT 
cell  frequency,  number,  phenotype  and 
effector  functions  were  assessed,  in  direct 
comparison  with  mainstream  T  cells,  inthe peripheral blood of recipients at
monthly intervals up to 18 mo post-
hHSCT, correlating their emergence with
disease relapse and analyzing their recon-
stitution and maturation kinetics using
mathematical models. The data on the
reconstitution dynamics of iNKT cells was
further reinforced by adding a cross-
sectional analysis in a second group of 11
patients, who were in clinical remission for
2–6 y post-hHSCT.
Two major findings were obtained
(Fig.1B). First, we identified a clearly
different population dynamics of the
CD4
+ and CD4
- iNKT cell subsets. The
CD4
+ emerged first and increased in
the periphery at a rate twice faster than
that of the CD4
- cells. Both subsets
appeared with an immature CD161
-
phenotype; however, the CD4
- cells
matured markedly more rapidly than the
CD4
+ iNKT cells, reaching adult-like
frequency of CD61 and IFNc expression
already by 6 mo after their first detec-
tion. The CD4
+ iNKT cells remained
the most abundant subset up to 5–6y
post-hHSCT, when the CD4
- cells under-
went a brisk expansion resulting in the
CD4
-   CD4
+ iNKT cell ratio typical of
adults. These data suggested that the
making of a mature iNKT cell repertoire
is a slow process regulated by subset-
specific mechanisms. Second, we observed
a correlation between the presence of
iNKT cells and leukemia remission.
iNKT cells fully reconstituted in all 14
patients maintaining remission, whereas
they completely failed to reconstitute in
the 8 relapsing patients. Although the
number of patients analyzed was relatively
small, none of the best-known variables
(female-to-male combination, donor NK
Figure1. Schematic iNKT cell reconstitution dynamics and correlation with disease control following hHSCT in pediatric leukemia patients. A longitudinal
analysis of iNKT cell reconstitution in relation to disease remission was performed monthly for 18 mo post-hHSCT in 22 children affected by leukemia and
myelodisplasia. This data were integrated by a cross-sectional analysis of iNKT cell frequency and maturation in a second cohort of 11 leukemia patients
that were in stable remission from 1 to 8 y after transplantation. (A) Schematic illustration of the transplantation physiology in case of HLA-haploidentical
conditions. Donor CD34
+ HSC are T cell depleted to reduce the risk of GVHD due to donor/recipient HLA barrier. Patients are myeloablated to eradicate
malignant cells and eliminate the endogenous immune system and then infused with purified CD34
+ HSC. Pro-thymocytes, originated from transplanted
HSC that have reached the bone marrow, colonize the thymus and generate T and iNKT cells that are exported in the periphery. iNKT cells are detectable
in periphery of patients maintaining remission as early as 3 mo post-hHSCT and reach an average of . 10 iNKT/10
6 T cells in the 18 mo observation time,
whereas iNKT cells fail to reconstitute in relapsing patients, remaining on average , 20 iNKT/10
6 T cells. (B) Immunoreconstitution dynamics of human
iNKT cell following hHSCT. The left panel depicts the different dynamics followed by the CD4
+ and CD4
- iNKT cell subsets. The CD4
+ emerge before the
CD4
- ones in the periphery and remain the dominant subset up to 4–5 y post-transplant. The CD4
- cells undergo a massive expansion around 7 y
post-hHSCT, resulting in the CD4
- . CD4
+ iNKT cell ratio typical of adult healthy individuals. The right panel shows the dynamics of the terminal
NK-maturation of the two iNKT cells subsets, as defined by the acquisition of CD161 (NKPR1a-c). Both CD4
+ and CD4
- subsets emerge in the periphery
with an immature CD161
- phenotype. The CD4
- subset matures markedly more rapidly than the CD4
+ cells and reaches adult CD161-expression levels
already by 2 y post-hHSCT, whereas the CD4
+ iNKT cells have not yet completed their NK-maturation after 7 y post-transplantation.
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+ cells
infused) could predict the risk of disease
recurrence. The critical parameter in the
immune reconstitution was the iNKT/T
cell ratio, which was on average 20 iNKT
cells/10
6T cells in relapsed patients and
100 iNKT cells/10
6T cells in patients
maintaining remission, during the same
observation time. Although we do not
yet have clear mechanistic insight, these
findings suggested that, in the critical
equilibrium conditions represented by
the early post-transplantation period,
iNKT cells are an essential part of the
effector mosaic that maintains the control
on the minimal residual leukemia cells
that might have escaped the preparative
regimen. This is consistent with other
human critical cancer contexts, such as
head and neck squamous cell carcinoma,
where the disease progression following
radiotherapy was found to correlate with
a very low iNKT/T cell ratio (, 47 iNKT
cells/10
6 T cells) present in the patients.
10
Our findings have also potential clinical
implications. The molecular determina-
tion of the iNKT cell reconstitution
trend following hHSCT could become a
predictive therapeutic marker. Further-
more, children who do not properly
reconstitute the iNKT cell compartment
within the first 2–6 mo after hHSCT
could receive infusions of donor-derived
iNKT cells to prevent possible leukemia
recurrence, with minimal risk of inducing
GVHD.
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